Eligo Bioscience is a young biotech that develops smart antibiotics for microbiome precision-editing.
Eligo Bioscience develops Eligobiotics, which are antimicrobials that programmed to target bacteria based on their genome.
Eligo Bioscience was founded in 2014 and is based in Paris, Ile-de-France, France.
Eligo Bioscience's Eligobiotics are protein-based nanodelivery vectors that contain a synthetic circuit encoding for a programmable RNA-guided nuclease.
Eligo Bioscience is backed by prominent investors such as Khosla Ventures, Seventure Partners, AGORANOV, & Worldwide Innovation Challenge.